Markets for Pharmaceutical Products11The authors thank Tom McGuire for editorial advice and improvements and participants at the Handbook conference for helpful suggestions
Fiona Scott Morton and
Chapter Chapter Twelve in Handbook of Health Economics, 2011, vol. 2, pp 763-823 from Elsevier
This chapter describes the market for pharmaceuticals, which exceeded $500 million in sales in 2010. The industry is also characterized by extensive regulation of almost every activity, from product development through manufacturing and marketing, which we summarize. We next describe the industry's market structure. Large, fully integrated, multinational firms that develop and market new drugs have historically dominated the industry, but the emergence of smaller firms focused on the application of biotechnology to drug development as well as firms that specialize in low-cost production of off-patent â€œgenericâ€ drugs has had an important impact on the market structure of the industry. The last two decades have seen a shift towards vertical specialization as well as many horizontal mergers. We discuss trends in the productivity of pharmaceutical research and incentives for innovation. We then summarize the pricing and marketing of drugs in the US and several other countries.
Keywords: pharmaceuticals; market structure; regulation; innovation; productivity; competition (search for similar items in EconPapers)
JEL-codes: L65 I11 L22 I18 D12 D43 (search for similar items in EconPapers)
References: Add references at CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
Full text for ScienceDirect subscribers only
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:eee:heachp:2-763
Access Statistics for this chapter
More chapters in Handbook of Health Economics from Elsevier
Bibliographic data for series maintained by Haili He ().